## Diagnosis: Type 1 Lepra Reaction (Reversal Reaction) **Key Point:** Type 1 lepra reaction is a delayed-type hypersensitivity (Type IV) reaction that occurs in immunologically unstable forms of leprosy: borderline tuberculoid (BT), borderline (BB), and borderline lepromatous (BL). It is characterized by acute inflammation of existing lesions and nerves. **Clinical Features of Type 1 Reaction:** - Sudden swelling, erythema, and inflammation of **existing lesions** (not new lesions) - Acute neuritis with nerve tenderness and thickening - Can occur before, during, or after MDT - No systemic symptoms (fever, constitutional symptoms are absent) - High bacillary index (unlike ENL, which occurs in high-bacillary-load patients) **Histopathology:** - Epithelioid granulomas with activated macrophages - Increased cellularity and inflammation within existing granulomas - NO immune complex deposition (distinguishes from ENL) - Langerhans cells and T-cell infiltration **High-Yield:** Type 1 reactions occur in **BT, BB, BL** (unstable forms), whereas ENL occurs in **LL and BL** (high bacillary load). The key distinguishing feature is histology: epithelioid granulomas (Type 1) vs. immune complexes (ENL). **Mnemonic: TYPE 1 vs. TYPE 2 LEPRA REACTIONS** - **Type 1 (Reversal):** Cell-mediated, **existing lesions**, epithelioid granulomas, unstable forms (BT, BB, BL), no fever - **Type 2 (ENL):** Immune complex, **new nodules**, neutrophilic infiltration, high-bacillary forms (LL, BL), fever present **Management:** - Continue MDT - Corticosteroids (prednisolone 0.5–1 mg/kg) for inflammation and neuritis - NSAIDs for mild cases - Physiotherapy for affected nerves **Clinical Pearl:** Acute neuritis in Type 1 reaction is a medical emergency because it can lead to permanent nerve damage and disability. Early aggressive anti-inflammatory therapy is crucial. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.